Contrasting Fresh Tracks Therapeutics (NASDAQ:FRTX) and Ikena Oncology (NASDAQ:IKNA)

Ikena Oncology (NASDAQ:IKNA) and Fresh Tracks Therapeutics (NASDAQ:FRTX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, earnings, profitability, valuation and dividends.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Ikena Oncology and Fresh Tracks Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ikena Oncology	0	1	1	0	2.50
Fresh Tracks Therapeutics	0	0	0	0	0.00

Ikena Oncology presently has a consensus price target of $3.00, suggesting a potential upside of 75.44%. Given Ikena Oncology’s stronger consensus rating and higher probable upside, equities analysts clearly believe Ikena Oncology is more favorable than Fresh Tracks Therapeutics.

Risk and Volatility

Ikena Oncology has a beta of 0.48, meaning that its share price is 52% less volatile than the S&P 500. Comparatively, Fresh Tracks Therapeutics has a beta of 0.48, meaning that its share price is 52% less volatile than the S&P 500.

Profitability

This table compares Ikena Oncology and Fresh Tracks Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Ikena Oncology	N/A	-36.88%	-33.08%
Fresh Tracks Therapeutics	N/A	N/A	N/A

Valuation and Earnings

This table compares Ikena Oncology and Fresh Tracks Therapeutics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ikena Oncology	$9.16 million	9.01	-$68.17 million	($1.23)	-1.39
Fresh Tracks Therapeutics	$8.01 million	0.53	-$5.69 million	($1.41)	-0.51

Fresh Tracks Therapeutics has lower revenue, but higher earnings than Ikena Oncology. Ikena Oncology is trading at a lower price-to-earnings ratio than Fresh Tracks Therapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

75.0% of Ikena Oncology shares are held by institutional investors. Comparatively, 25.0% of Fresh Tracks Therapeutics shares are held by institutional investors. 5.9% of Ikena Oncology shares are held by insiders. Comparatively, 0.2% of Fresh Tracks Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Ikena Oncology beats Fresh Tracks Therapeutics on 8 of the 12 factors compared between the two stocks.

About Ikena Oncology

Ikena Oncology, Inc. operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway. The company also develops IK-595, a molecular glue designed to trap MEK and RAF in an inactive complex. Ikena Oncology, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

About Fresh Tracks Therapeutics

Fresh Tracks Therapeutics, Inc. does not have significant operations. Previously, the company was engaged in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. Fresh Tracks Therapeutics, Inc. was founded in 2009 and is headquartered in Boulder, Colorado.